CD86 and neoplasm: Overall, our results suggest that the expression of co-stimulatory molecules (CD86), antigen presentation machinery (HLA-DR), and co-inhibitory molecules (PD-L1) in DCs, and their ability to activate T cells were impacted upon interaction with tumor organoids.